D one was followed up instudy. Twelve patients continued the study treatment withoutFigure 3. Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population). doi:10.1371/journal.pone.0054279.gTelbivudine 6 Conditional Tenofovir: 52-Week DataTable 3. Most common ( 5 ) all-cause adverse events through Week 52 (safety population).Tenofovir intensification (n = 46) n ( ) Total patients with any event Myalgia Headache Upper respiratory tract infection Dyspepsia Arthralgia Diarrhoea Nausea Dizziness Fatigue Pain in extremity Pyrexia Vomiting Nasopharyngitis Upper abdominal pain Cough Telbivudine monotherapy Telbivudine only (n = 59) period 42 (71.2) 10 (16.9) 6 (10.2) 4 (6.8) 4 (6.8) 1 (1.7) 3 (5.1) 2 (3.4) 3 (5.1) 3 (5.1) 3 (5.1) 3 (5.1) 1 (1.7) 3 (5.1) 0 (0.0) 0 (0.0) 23 (50.0) 3 (6.5) 5 (10.9) 4 (8.7) 0 (0.0) 2 (4.3) 1 (2.2) 0 (0.0) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 0 (0.0) 0 (0.0) 3 (6.5) 2 (4.3) Tenofovir add on period 20 (43.5) 1 (2.2) 1 (2.2) 1 (2.2) 3 (6.5) 3 (6.5) 1 (2.2) 3 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.5) 1 (2.2) 0 (0.0) 1 (2.2) Overall*(N = 105) 73 (69.5) 13 (12.4) 12 (11.4) 9 (8.6) 7 (6.7) 5 (4.8) 5 (4.8) 5 (4.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 3 (2.9) 3 (2.9)*Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall MedChemExpress ML-240 numbers with an indicated event may therefore be less than the row total. doi:10.1371/journal.pone.0054279.tinterruption and one discontinued. Six myalgia cases were not suspected to be related to study treatment. Grade 3 or grade 4 creatine kinase elevations occurred in two patients in the monotherapy group (one grade 3 at Week 48 and one grade 4 at Week 49) and two intensification group patients (one grade 3 at Week 16 on telbivudine alone and another at Week 52 on telbivudine plus tenofovir). Two patients experienced an ALT flare. Both occurred under initial telbivudine monotherapy (Weeks 4 
and 8) in patients who later received intensification. Both flare patients had undetectable HBV DNA at Week 52. There were no renal events other than one treatment-unrelated case of moderate renal colic. No patient reported with creatinine increase. Mean Week 52 GFR was significantly higher than baseline in both treatment groups. Overall mean GFR change to week 52 by the MDRD and the Cockcroft-Gault formulae was 6.9 mL/min and 8.3 mL/min, respectively, in the monotherapy group; and 7.4 mL/min and 6.2 mL/min, respectively, in the intensification group (P,0.01 for all comparisons). Figure 4 shows week 52 GFR changes (MDRD) stratified by baseline GFR. No significant GFR decline was noted in patients with low baseline GFR, Mirin manufacturer although numbers were small.DiscussionIn providing a framework for the conditional intensification of monotherapy, the Roadmap [16] provides a rational approach to improve long-term outcomes, while minimizing the risk of drug resistance due to continued sub-optimal monotherapy or adverse events associated with unnecessary combination treatment. Under the Roadmap, nucleosides with a low genetic barrier to resistance (e.g. lamivudine) are intensified with a non-cross-resistant second agent if any HBV replication is still measurable at Week 24. Although telbivudine is more potent than lamivudine with less ontreatment resistance [5,15], it is closest to lamivudine in terms of the features informing Roadmap decisions; and intensification was applied to any patient with detectable Week 24 viremia. The requirement for.D one was followed up instudy. Twelve patients continued the study treatment withoutFigure 3. Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population). doi:10.1371/journal.pone.0054279.gTelbivudine 6 Conditional Tenofovir: 52-Week DataTable 3. Most common ( 5 ) all-cause adverse events through Week 52 (safety population).Tenofovir intensification (n = 46) n ( ) Total patients with any event Myalgia Headache Upper respiratory tract infection Dyspepsia Arthralgia Diarrhoea Nausea Dizziness Fatigue Pain in extremity Pyrexia Vomiting Nasopharyngitis Upper abdominal pain Cough Telbivudine monotherapy Telbivudine only (n = 59) period 42 (71.2) 10 (16.9) 6 (10.2) 4 (6.8) 4 (6.8) 1 (1.7) 3 (5.1) 2 (3.4) 
3 (5.1) 3 (5.1) 3 (5.1) 3 (5.1) 1 (1.7) 3 (5.1) 0 (0.0) 0 (0.0) 23 (50.0) 3 (6.5) 5 (10.9) 4 (8.7) 0 (0.0) 2 (4.3) 1 (2.2) 0 (0.0) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 0 (0.0) 0 (0.0) 3 (6.5) 2 (4.3) Tenofovir add on period 20 (43.5) 1 (2.2) 1 (2.2) 1 (2.2) 3 (6.5) 3 (6.5) 1 (2.2) 3 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.5) 1 (2.2) 0 (0.0) 1 (2.2) Overall*(N = 105) 73 (69.5) 13 (12.4) 12 (11.4) 9 (8.6) 7 (6.7) 5 (4.8) 5 (4.8) 5 (4.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 4 (3.8) 3 (2.9) 3 (2.9)*Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be less than the row total. doi:10.1371/journal.pone.0054279.tinterruption and one discontinued. Six myalgia cases were not suspected to be related to study treatment. Grade 3 or grade 4 creatine kinase elevations occurred in two patients in the monotherapy group (one grade 3 at Week 48 and one grade 4 at Week 49) and two intensification group patients (one grade 3 at Week 16 on telbivudine alone and another at Week 52 on telbivudine plus tenofovir). Two patients experienced an ALT flare. Both occurred under initial telbivudine monotherapy (Weeks 4 and 8) in patients who later received intensification. Both flare patients had undetectable HBV DNA at Week 52. There were no renal events other than one treatment-unrelated case of moderate renal colic. No patient reported with creatinine increase. Mean Week 52 GFR was significantly higher than baseline in both treatment groups. Overall mean GFR change to week 52 by the MDRD and the Cockcroft-Gault formulae was 6.9 mL/min and 8.3 mL/min, respectively, in the monotherapy group; and 7.4 mL/min and 6.2 mL/min, respectively, in the intensification group (P,0.01 for all comparisons). Figure 4 shows week 52 GFR changes (MDRD) stratified by baseline GFR. No significant GFR decline was noted in patients with low baseline GFR, although numbers were small.DiscussionIn providing a framework for the conditional intensification of monotherapy, the Roadmap [16] provides a rational approach to improve long-term outcomes, while minimizing the risk of drug resistance due to continued sub-optimal monotherapy or adverse events associated with unnecessary combination treatment. Under the Roadmap, nucleosides with a low genetic barrier to resistance (e.g. lamivudine) are intensified with a non-cross-resistant second agent if any HBV replication is still measurable at Week 24. Although telbivudine is more potent than lamivudine with less ontreatment resistance [5,15], it is closest to lamivudine in terms of the features informing Roadmap decisions; and intensification was applied to any patient with detectable Week 24 viremia. The requirement for.